Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F, Mark JR, Stamatakis L, Hoffman-Censits JH, Viterbo R, Greenberg RE, Churilla TM, Horwitz EM, Hallman MA, Smaldone MC, Uzzo R, Chen DYT, Kutikov A, Plimack ER.
Geynisman DM, et al. Among authors: mark jr.
J Clin Oncol. 2024 Dec 16:JCO2401214. doi: 10.1200/JCO-24-01214. Online ahead of print.
J Clin Oncol. 2024.
PMID: 39680823